Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis

Inclusion Criteria: * Informed and having signed the study consent form * Age ≥ 18 years * NICU according to the Standardization of Uveitis Nomenclature (SUN) criteria * Complete ophthalmological response for ≥ 48 weeks (96 weeks for uveitis related to Behçet's disease), all treatments combined * On ADA 40mg / 14 days for ≥ 24 weeks (i.e. achievement of the steady state for ADA concentrations) * Not having received systemic corticosteroid therapy for ≥ 12 weeks Exclusion Criteria: * Inability or refusal to understand and/or sign the informed consent form to participate in the study. * Inability and/or refusal to carry out the follow-up examinations required for the study. * Modification of any background immunomodulatory treatment (e.g. methotrexate, hydroxychloroquine, mycophenolate, etc.) associated with ADA, during the 12 weeks prior to inclusion. * Uveitis suspected or proven to be of infectious origin * Planned surgery (or other foreseeable medical event) requiring discontinuation of ADA for the duration of the study.